Department of Pharmacology, Drug Development and Therapeutics, University of Turku, 20014 Turku, Finland.
Eur J Clin Pharmacol. 2013 Feb;69(2):261-7. doi: 10.1007/s00228-012-1328-0. Epub 2012 Jun 17.
Statin use has increased in older age groups, although there is little evidence for the benefits of statin therapy in the elderly, especially in low-risk persons. The aim of this paper is to describe recent trends in the prevalence and incidence of statin use among the Finnish older population, according to the person's estimated cardiovascular (CV) event risk.
We conducted a register study covering the whole community-dwelling population of Finland, aged >70 years in 2000-2008 (N = 883,051). Data on reimbursed purchases of statins, antidiabetic and CV drugs, and pre-existing CV diseases were retrieved from comprehensive national registers. We stratified each person into low, moderate or high CV risk category, and according to age (70-74, 75-79, and >80 years) and sex.
Between 2000 and 2008, the age-sex-standardized prevalence of statin use tripled from 12.2 % to 38.7 % (rate ratio 3.0, 95 % CI 3.0-3.1), and the incidence almost doubled (from 3.7 % to 6.8 %; rate ratio 1.8, 95 % CI 1.8-1.9). The prevalence and incidence of statin use were consistently highest among high-risk persons. The greatest relative increases were observed in persons aged >80 years and in those at low risk; however, the proportion of statin users at low CV risk remained the same (∼7 % of all users).
Statin prescribing is shifting towards older age groups. A substantial increase in prevalence and incidence was seen across all risk categories, but the channeling of statin use towards high-risk persons remained unchanged.
尽管在老年人中他汀类药物治疗的益处证据有限,尤其是在低危人群中,他汀类药物的使用在老年人群体中有所增加。本文旨在根据个体的心血管(CV)事件风险描述芬兰老年人群中他汀类药物使用的流行率和发生率的近期趋势。
我们进行了一项基于登记的研究,涵盖了 2000-2008 年芬兰年龄>70 岁的所有社区居住人群(n=883051)。从综合国家登记册中检索了他汀类药物、降糖药和心血管药物的报销购买情况以及预先存在的心血管疾病数据。我们将每个人分为低、中或高 CV 风险类别,并根据年龄(70-74、75-79 和>80 岁)和性别进行分层。
2000 年至 2008 年间,他汀类药物使用率的年龄-性别标准化患病率从 12.2%增至 38.7%(率比 3.0,95%CI 3.0-3.1),发病率几乎翻了一番(从 3.7%增至 6.8%;率比 1.8,95%CI 1.8-1.9)。高风险人群的他汀类药物使用率始终最高。在>80 岁的人群和低危人群中观察到相对增幅最大;然而,低 CV 风险的他汀类药物使用者比例保持不变(约占所有使用者的 7%)。
他汀类药物的处方正在向老年人群转移。所有风险类别中均出现了使用率和发病率的大幅增加,但将他汀类药物用于高危人群的趋势没有改变。